Had radiation 2018 then it metastases in 2021 so had L2 lumbar nuked and back on Zolodex 2 years later it increased but slow growing in L1 and hip so they want me on Enzalutamide Note it's the latest COPY Xtandi was granted an FDA fast track and later approved in metastatic castration-sensitive prostate cancer (mCSPC) by late 2019. In May, the oral treatment also scored a European nod for that indication, which carries a grim median survival of just three to four years, Astellas says. U.S. regulators already approved Xtandi in mCSPC and nonmetastatic CRPC (nmCRPC).
For its part, androgen receptor inhibitor Erleada, J&J's follow-up to aging Zytiga, was also approved in mCSPC in 2019 and in nmCRPC a year before that. (so Phizer Enzalutamide or Extandi seems superior outcomes

looking at why not now. https://health.ucsd.edu/news/releases/Pages/2022-10-05-patient-first-in-region-to-receive-new-treatment-for-advanced-prostate-cancer.aspx